Feng Liang, He Haijun, Xiong Xi, Xia Kai, Qian Shuangjie, Ye Qianqian, Feng Feifei, Zhou Shuoting, Hong Xianchai, Liu Yiming, Xie Chenglong
Department of Neurology, Qilu Hospital of Shandong University, Jinan, China.
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Front Aging Neurosci. 2022 Oct 28;14:1022274. doi: 10.3389/fnagi.2022.1022274. eCollection 2022.
We aimed to examine whether plasma-derived phosphoglycerate mutase 5 (PGAM5) can be a biomarker for Parkinson's disease (PD) diagnosis as well as its association with the severity of motor/non-motor manifestations of PD.
We enrolled 124 patients with PD (PD group) and 50 healthy controls (HC group). We measured plasma PGAM5 levels using a quantitative sandwich enzyme immunoassay. Patients with PD underwent baseline evaluations using the Unified Parkinson's Disease Rating Scale (UPDRS), while participants in both groups were evaluated using scales for non-motor manifestations. Receiver operating characteristic curves were used to evaluate the predictive utility of plasma PAMG5 alone and combined with other factors.
Plasma PAMG5 levels were significantly higher in the PD group; the area under the curve (AUC) of plasma PGAM5 levels alone was 0.76. The AUC values for elderly participants and patients without hypertension were 0.78 and that for was 0.79. Notably, plasma PGAM5 levels combined with plasma oligomeric α-synuclein (α-syn) and the score of the REM sleep behavior disorder questionnaire-Hong Kong (RBDQ-HK) showed AUC values of 0.80 and 0.82. Multivariable logistic analysis revealed that plasma PAMG5 levels were independently associated with PD (odds ratio,1.875 [95% confidence interval 1.206-2.916], = 0.005) but not the severity of motor/non-motor manifestations of PD.
Plasma PGAM5 is an independent biomarker for PD, especially among elderly patients (age > 60 years) and patients without hypertension. The predictive utility of PGAM5 was improved when combined with plasma oligomeric α-syn or the RBDQ-HK score.
我们旨在研究血浆来源的磷酸甘油酸变位酶5（PGAM5）是否可作为帕金森病（PD）诊断的生物标志物，以及其与PD运动/非运动表现严重程度的关联。
我们纳入了124例PD患者（PD组）和50名健康对照者（HC组）。我们使用定量夹心酶免疫测定法测量血浆PGAM5水平。PD患者使用统一帕金森病评定量表（UPDRS）进行基线评估，而两组参与者均使用非运动表现量表进行评估。受试者工作特征曲线用于评估血浆PAMG5单独以及与其他因素联合使用时的预测效用。
PD组血浆PAMG5水平显著更高；血浆PGAM5水平单独的曲线下面积（AUC）为0.76。老年参与者和无高血压患者的AUC值分别为0.78和0.79。值得注意的是，血浆PGAM5水平与血浆寡聚α-突触核蛋白（α-syn）以及快速眼动睡眠行为障碍问卷-香港版（RBDQ-HK）评分联合时，AUC值分别为0.80和0.82。多变量逻辑分析显示，血浆PAMG5水平与PD独立相关（优势比，1.875 [95%置信区间1.206 - 2.916]，P = 0.005），但与PD运动/非运动表现的严重程度无关。
血浆PGAM5是PD的独立生物标志物，尤其是在老年患者（年龄>60岁）和无高血压患者中。当与血浆寡聚α-syn或RBDQ-HK评分联合使用时，PGAM5的预测效用得到改善。
